Three Months Ended

(In thousands)

March 31, 2020

Operating expense:

As Reported

Adjustment

As Revised

% Change

Cost of goods sold

$

 —

86

$

86

100

%

Research and Development

999

96

1,095

10

%

General and administrative

3,161

(182)

2,979

(6)

%

Total operating expenses

$

4,160

$

4,160

Nine Months Ended

(In thousands)

March 31, 2020

Operating expense:

As Reported

Adjustment

As Revised

% Change

Cost of goods sold

$

 —

404

$

404

100

%

Research and Development

2,864

126

2,990

 4

%

General and administrative

8,728

(530)

8,198

(6)

%

$

11,592

$

11,592

As Reported:

Three Months Ended March 31, 2020 (in thousands)

iBio, Inc.

iBio CDMO

Eliminations

Total

Cost of goods sold

$

 —

$

 —

$

 —

$

 —

Research and Development

78

1,722

(801)

999

General and administrative

1,584

1,774

(197)

3,161

As Revised:

Three Months Ended March 31, 2020 (in thousands)

iBio, Inc.

iBio CDMO

Total

Cost of goods sold

$

72

14

$

 —

$

86

Research and Development

14

1,882

(801)

1,095

General and administrative

1,576

1,600

(197)

2,979

As Reported:

Nine Months Ended March 31, 2020 (in thousands)

iBio, Inc.

iBio CDMO

Total

Cost of goods sold

$

 —

$

 —

$

 —

$

 —

Research and Development

3,152

2,005

(1,307)

3,850

General and administrative

3,090

7,091

(1,073)

9,108

As Revised:

Nine Months Ended March 31, 2020 (in thousands)

iBio, Inc.

iBio CDMO

Total

Cost of goods sold

$

341

63

$

 —

$

404

Research and Development

2,829

2,454

(1,307)

3,976

General and administrative

3,072

6,579

(1,073)

8,578